機構：BA.5變異株傳播速度加快 關注港股新冠相關標的
根據國外研究資料顯示，BA.5變異株傳播速度加快，免疫逃逸能力提高，但總體而言，和此前流行的奧密克戎變異株BA.2相比，發生危重症和病死率的風險未發現明顯差異。研究結果也顯示疫苗接種仍能有效預防BA.5感染後發生的危重症和死亡。
投資建議
在把握港股估值修復機會的同時建議佈局景氣賽道及超跌核心資產，未來建議關注：
1)創新藥：傳奇生物CART成功於FDA獲批是創新藥出海的優秀先例，長期看醫藥創新仍是主旋律，建議緊密跟蹤相關企業的海外臨牀試驗進展，重視相關潛力品種的海外市場空間。建議關注信達生物(1801.HK)、康方生物-B(9926.HK)等。
2)醫療器械：短期市場對器械集採預期較爲悲觀，相關標的表現較爲低迷；長期看，板塊子賽道衆多，分子診斷及微創機器人等子賽道潛力巨大，龍頭企業和創新企業具有壁壘。建議關注機器人賽道優質標的微創機器人-B(2252.HK)，以及癌症早篩標的諾輝健康-B(6606.HK)、眼科AI篩查優質標的鷹瞳科技-B(2251.HK)。
3)醫療服務：醫療服務滲透率低，需求增長前景廣闊，建議關注腫瘤醫療服務標的海吉亞醫療(6078.HK)、港股植髮第一股雍禾醫療(2279.HK)等。
4)CXO：CXO行業目前估值相對合理，具有配置的性價比，國內產業鏈具備全球競爭優勢，受益於海內外下遊需求增長，行業高景氣可以持續。長期看推薦一體化產業龍頭藥明康德(2359.HK)、康龍化成(3759.HK；300759.SZ)，藥明生物(2269.HK)。
5)疫苗及新冠治療藥：疫情週期超預期，防疫需求仍然很大。疫苗建議關注康希諾生物-B(6185.HK)、三葉草生物-B(2197.HK)，新冠治療藥建議關注君實生物(1877.HK)、先聲藥業(2096.HK)、歌禮制藥-B(1672.HK)、騰盛博藥-B(2137.HK)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
